NeurAxis (NASDAQ:NRXS – Get Free Report) is expected to be posting its results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $2.10 million for the quarter.
NeurAxis Stock Performance
Shares of NASDAQ:NRXS opened at $7.13 on Monday. The firm has a market capitalization of $89.54 million, a PE ratio of -3.87 and a beta of 1.38. NeurAxis has a 52-week low of $2.21 and a 52-week high of $9.33. The firm has a fifty day moving average of $6.83 and a 200 day moving average of $6.63.
Analyst Ratings Changes
Separately, Zacks Research upgraded NeurAxis to a “hold” rating in a report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.
About NeurAxis
NeurAxis, Inc (NASDAQ: NRXS) is a medical technology company focused on developing and commercializing non-invasive neuromodulation therapies for functional gastrointestinal and other nervous-system-related disorders. The company’s approach is designed to influence neural signaling through targeted electrical stimulation.
NeurAxis’s principal product is IB-Stim, a prescription, percutaneous electrical nerve-field stimulation device intended for use in adolescents with functional abdominal pain associated with irritable bowel syndrome and related functional gastrointestinal disorders.
Featured Stories
- Five stocks we like better than NeurAxis
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
